Highlight
• Povetacicept, a dual BAFF and APRIL inhibitor, significantly reduced proteinuria in IgA nephropathy by week 36.
• Markers of disease activity such as galactose-deficient IgA1 and hematuria also improved substantially with therapy.
• Adverse event rates were comparable between povetacicept and placebo groups, suggesting a favorable safety profile.
• The trial underscores the pathophysiological role of BAFF and APRIL in IgA nephropathy and support targeting these pathways therapeutically.
Study Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease. It is characterized by mesangial deposition of galactose-deficient immunoglobulin A1 (Gd-IgA1)-containing immune complexes, triggering inflammation and progressive kidney damage. Proteinuria is a key clinical marker of disease activity and progression. Despite the clinical burden, therapeutic options remain limited, focusing mainly on supportive care such as renin-angiotensin system blockade. The molecular drivers of IgAN include abnormal B-cell activation pathways involving B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which influence IgA-producing B-cell populations. Targeting these pathways offers a novel immunomodulatory approach to alter disease progression in IgAN.
Study Design
This ongoing phase 3, randomized, double-blind, placebo-controlled trial evaluates povetacicept, an engineered fusion protein designed to concurrently inhibit BAFF and APRIL by enhancing TACI (transmembrane activator and calcium-modulator and cyclophilin-ligand interactor)-Fc fragment binding. Eligible participants had biopsy-confirmed IgA nephropathy and were on stable background therapy. They were randomized 2:1 to receive subcutaneous povetacicept 80 mg or placebo every 4 weeks. The prespecified interim analysis focused on the primary endpoint of change in 24-hour urinary protein-to-creatinine ratio (UPCR) at 36 weeks. Secondary endpoints included changes in serum galactose-deficient IgA1 and hematuria resolution in those with baseline hematuria.
Key Findings
The interim efficacy analysis included 199 randomized participants (131 povetacicept, 68 placebo). By week 36, povetacicept recipients experienced a 52.0% median reduction in 24-hour UPCR, compared with a 4.3% reduction in the placebo group. The adjusted difference between groups was -49.8 percentage points (95% CI, -58.6 to -39.2), a statistically robust improvement with P<0.001.
Further supporting biological efficacy, serum galactose-deficient IgA1 levels decreased by 77.4% in the treatment group but increased by 9.1% in placebo recipients, with an adjusted difference of -79.3 percentage points (95% CI, -82.2 to -75.9; P<0.001). Hematuria resolution was observed in 85% of treated participants compared to 23% of placebo-treated participants, yielding an adjusted difference of 62 percentage points (95% CI, 45 to 78; P<0.001).
Regarding safety, adverse events occurred in 75% of the povetacicept group and 78% of placebo. Serious adverse events (SAEs) were low and balanced between groups (3% vs. 4%, respectively). The comparable safety profiles suggest povetacicept is well tolerated at the tested dose and duration.
Expert Commentary
This interim analysis from a large, rigorously designed phase 3 trial highlights the therapeutic potential of targeting both BAFF and APRIL pathways in IgA nephropathy. The magnitude of proteinuria reduction and improvement in disease-specific biomarkers, such as galactose-deficient IgA1, strengthens the mechanistic rationale that aberrant B-cell signaling drives pathogenic IgA1 production. Hematuria resolution further illustrates potential clinical benefits across multiple disease manifestations.
While promising, it is important to consider the limitations due to interim nature of the results; longer follow-up is necessary to evaluate effects on hard renal outcomes such as glomerular filtration rate preservation or end-stage kidney disease. Additionally, generalizability will be informed by subsequent data across diverse populations. The balanced safety data provide reassurance, but vigilance for immunosuppression-related risks remains prudent.
Current IgAN management guidelines focus on supportive measures; this study’s findings may pave the way for novel disease-modifying strategies tailored to underlying immunopathology. Future research should explore combination approaches, optimal patient selection, and long-term safety to fully define povetacicept’s role in clinical practice.
Conclusion
The phase 3 interim results demonstrate that povetacicept significantly reduces proteinuria and key disease biomarkers in IgA nephropathy patients compared to placebo, with comparable safety profiles. These findings reinforce BAFF and APRIL as critical therapeutic targets and suggest povetacicept as a promising immunomodulatory agent that could change the treatment landscape for IgAN.
Funding and Trial Registration
This trial was funded by Vertex Pharmaceuticals. Clinical trial registration number: NCT06564142 (RAINIER AIS-D08).
References
1. Barratt J, Zhang H, Han SH, et al. Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy. N Engl J Med. 2026 Oct 23; PMID: 42912669.
2. Suzuki H, Novak J. IgA nephropathy: A perspective for 2021. Kidney Int. 2021;99(3):443-454.
3. Floege J, Feehally J. IgA nephropathy: Clinical features and immunopathogenesis. Nephrol Dial Transplant. 2018;33(6):848-855.
